How Elon Musk’s Terafab Megaproject and a $674B Market Cap Sent ASML Stock Surging

The scale is staggering. Musk initially spoke of a roughly $25 billion investment, but by May 2026, SpaceX had filed Texas regulatory documents showing a minimum first-phase cost of $55 billion — with potential total expansion costs reaching $119 billion . That would make it one of the most expensive semiconductor projects ever proposed on American soil .

For ASML, the Dutch company that holds a monopoly on the extreme ultraviolet (EUV) lithography machines required to manufacture leading-edge chips, Terafab is a revenue engine of enormous proportions. ASML CEO Christophe Fouquet confirmed in May 2026 that he had spoken directly with Musk about the project and described it as “very serious” . He told Reuters he expects the first chips to be produced within months of tool installation, using ASML’s high-numerical-aperture EUV systems . Analysts have noted that ASML’s EUV order book is already full into 2029 — and Terafab would require dozens of additional machines, extending that visibility even further .

A Record Market Cap Months in the Making

While Musk’s endorsement grabbed headlines, ASML’s rally had been building all year. The stock was already up roughly 35% year-to-date in 2026 before his tweet . The first major catalyst arrived on January 15, when TSMC — ASML’s largest customer — announced record 2026 capital expenditures of $52–56 billion . ASML’s market cap surged past $500 billion that same day, cementing its position as Europe’s most valuable technology company .

The momentum continued through spring. Strong Q4 2025 earnings and raised 2026 guidance kept analysts bullish , and on June 3, ASML closed at a $668 billion market cap, surpassing the previous European record of $650 billion set by Novo Nordisk in 2024 . The company was already operating at historic heights when Musk’s tweet landed.

Then came the Musk catalyst. ASML confirmed on June 7 that Musk would speak virtually at its internal technology conference on June 11–12 to pitch the Terafab vision . The stock surged 5.81% the next trading day, pushing the market cap to $674 billion . For institutional investors, the logic was straightforward: Musk’s public endorsement was effectively a signal that Terafab was real and that ASML would be its primary equipment supplier.

The Employee Boycott: Real Friction, No Market Impact

Not everyone at ASML welcomed Musk’s appearance. When news spread that the SpaceX and Tesla CEO would keynote the company’s internal tech conference in Den Bosch, employees voiced strong criticism on internal communication channels . The Dutch newspaper Eindhovens Dagblad and DutchNews.nl reported that some staff threatened to boycott the event, arguing that Musk’s political views clash with ASML’s corporate values . The controversy was widely covered in the Dutch press .

From a market perspective, however, the backlash was a non-event. MarketBeat noted that the boycott reports added a “small reputational overhang” but that the direct business impact appeared limited . The stock hit its all-time high on the same day the boycott news broke, underscoring a straightforward investor calculus: the revenue from Terafab matters more than internal culture debates.

It’s worth noting this is not ASML’s only recent labor friction. In March 2026, more than 1,000 employees staged walkouts at the company’s Veldhoven headquarters to protest plans to cut 1,700 jobs — roughly 4–5% of the global workforce . Unions demanded an end to forced layoffs and better severance terms . Those protests were unrelated to Musk and were rooted in ASML’s own restructuring amid what CEO Fouquet described as a “challenging market environment” with flat 2026 revenue expectations . But like the Musk boycott, the labor unrest did not derail the stock.

The Bigger Narrative: AI Demand, Monopoly Power, and Execution Risk

The ASML rally is not a single-event story — it’s a stacking of reinforcing catalysts. A global AI buildout has driven sustained demand for advanced chips, which in turn fuels demand for ASML’s EUV machines. TSMC’s record spending plans validated that trend in January. ASML’s Q4 2025 results and raised guidance reinforced it in April. The record market cap milestone in June provided a psychological anchor. Then Terafab — and Musk’s high-profile endorsement — added a concrete, multi-year demand signal that investors could model directly.

ASML’s monopoly position is the thread that ties it all together. The company is the sole manufacturer of EUV lithography equipment capable of producing sub-2nm chips . Every major chipmaker building leading-edge capacity — TSMC, Intel, Samsung, and now the Musk-led Terafab consortium — must buy from ASML. That monopoly has translated into €32.7 billion in net sales for 2025 and a 2026 guidance range of €34–39 billion .

The main risk is execution. Terafab’s estimated costs have already ballooned from roughly $25 billion to $55–119 billion, and the project remains unproven at this scale . If the project stalls or funding falls through, the demand signal that helped push ASML to $674 billion could reverse. But for now, investors are betting that the momentum is real — and that ASML, with its full order book and unrivaled technology, is the most direct way to play it.